The heterogenous expression of B-cell maturation antigen (BCMA), which is the primary CAR target in multiple myeloma, and BCMA shutdown under CAR-T-cell pressure pose crucial issues in the CAR-T-cell therapy of multiple myeloma [22,23]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.